LEADER 01477nas  2200541-a 450 
001 9910141529303321
005 20210913213021.0
035   $a(OCoLC)819760131
035   $a(CKB)2670000000320322
035   $a(CONSER)--2016243009
035   $a(MiFhGG)5UCD
035   $a(MiAaPQ)3933158
035   $a(DE-599)ZDB2706272-7
035   $a(EXLCZ)992670000000320322
100   $a20121130a20129999  ---         a
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aImmunoTargets and therapy
210   $aAuckland, NZ $cDove Medical Press
300   $aRefereed/Peer-reviewed
311   $a2253-1556 
517 3 $aITT
531   $aIMMUNOTARGETS THER
531 10$aImmunotargets Ther
531 0 $aImmunoTargets ther.
606   $aImmunotherapy$vPeriodicals
606   $aImmunotherapy
606   $aImmunology$2ebps
606   $aImmunotherapy$2ebps
606   $aImmunotherapy$2fast$3(OCoLC)fst00968044
608   $aFulltext.
608   $aInternet Resources.
608   $aPeriodicals.
608   $aPeriodicals.$2fast
615  0$aImmunotherapy
615 12$aImmunotherapy.
615  7$aImmunology.
615  7$aImmunotherapy.
615  7$aImmunotherapy.
676   $a616.07905
712 02$aDove Medical Press Ltd.
906   $aJOURNAL
912   $a9910141529303321
996   $aImmunoTargets and therapy$91947254
997   $aUNINA